Real-Life Use of Adjuvant Trastuzumab in Early Breast Cancer
the Cancer Therapy Advisor take:
Effectiveness of adjuvant trastuzumab in patients with early-stage HER2-positive breast cancer in real life is comparable to randomized clinical trials, according to an article published online in the journal The Oncologist.
Participants of this study included patients with stage I through III invasive breast cancer (diagnosed between 2005 and 2007) from five hospitals in the southeast of The Netherlands.
Results showed that 476 patients out of 2,684 (17.7%) had a HER2-positive malignant tumor. Although 251 (52.7%) of these patients had an indication for treatment with trastuzumab, only 196 (78.1%) actually received the treatment.
Patients treated with trastuzumab had a 5-year disease-free survival of 80.7% (n = 230) compared with a five-year disease-free survival of 68.2% (n = 246) for patients not treated with trastuzumab (P = 0.0023).
The five-year overall survival rate for the trastuzumab cohort was 90.7% versus 77.4% for the patients not treated with trastuzumab.
After adjusting for confounders, the hazard ratio for recurrence was 0.63 (95% CI: 0.37, 1.06) for trastuzumab.
The study suggests that real-life studies be considered when introducing new drugs because they can provide further insight into specific patient groups that may not be found in randomized trials.
Effectiveness of adjuvant trastuzumab in early-stage HER2-positive breast cancer in real life comparable to randomized clinical trials.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes
- Tool for Assessing Frailty Predicts Survival in Newly Diagnosed Multiple Myeloma
- Analysis Supports Flat Dose of Nivolumab 480 mg Every 4 Weeks
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Role of miR-125a-5p Clarified in Bladder Cancer
- Bladder Cancer Clinical Features Linked to EGFR and HER-2 Expression
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- A Vegan Diet and Cancer
- The Optimal Neoadjuvant Regimen of Checkpoint Inhibitors in High-Risk Melanoma Is Unclear